Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Landos Biopharma Inc (NQ: LABP ) N/A UNCHANGED Last Price Updated: 4:00 PM EDT, May 23, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Landos Biopharma Inc < Previous 1 2 3 Next > LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP May 11, 2024 From Kahn Swick & Foti, LLC Via Business Wire LABP Stock Earnings: Landos Biopharma Misses EPS for Q1 2024 May 09, 2024 LABP stock results show that Landos Biopharma missed analyst estimates for earnings per share the first quarter of 2024. Via InvestorPlace Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook April 26, 2024 AbbVie impresses with Q1 results: EPS beats at $2.31 (-6.1% Y/Y), net revenue exceeds at $12.31 billion (+0.7%). Notable: Immunology sales, Humira vs. biosimilars, oncology gains. Via Benzinga BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: AdTheorent Holding Company, Inc. (Nasdaq – ADTH), Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN) April 01, 2024 From Brodsky & Smith LLC Via GlobeNewswire Recap: Landos Biopharma Q4 Earnings March 21, 2024 Via Benzinga LANDOS BIOPHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Landos Biopharma, Inc. - LABP March 27, 2024 From Kahn Swick & Foti, LLC Via Business Wire Nasdaq Turns Higher; Akanda Shares Plunge March 25, 2024 U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning higher on Monday. The Dow traded down 0.37% to 39,331.42 while the NASDAQ rose 0.06% to 16,439.38. The S&P 500 also... Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Monday's Intraday Session March 25, 2024 Via Benzinga Is the Stock Market Closed on Good Friday 2024? March 25, 2024 Investors are wondering if the stock market is closed on Good Friday 2024 as they prepare for the upcoming Easter weekend. Via InvestorPlace Landos Biopharma: Q3 Earnings Insights November 09, 2023 Via Benzinga Recap: Landos Biopharma Q1 Earnings May 12, 2023 Via Benzinga Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session March 25, 2024 Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news. Via Benzinga Why Is Landos Biopharma (LABP) Stock Up 168% Today? March 25, 2024 Landos Biopharma stock is up on Monday as LABP investors learn about a massive acquisition deal with AbbVie that values it at $137.5 million. Via InvestorPlace Crude Oil Moves Higher; US New Home Sales Fall In February March 25, 2024 U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 100 points on Monday. The Dow traded down 0.22% to 39,389.17 while the NASDAQ fell 0.15% to 16,410.10. The... Via Benzinga Topics Stocks Exposures Fossil Fuels US Equities LABP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Landos Biopharma, Inc. Is Fair to Shareholders March 25, 2024 From Halper Sadeh LLC Via Business Wire Why Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday? March 25, 2024 AbbVie seals deal with Landos Biopharma at $20.42/share, totaling $137.5 million plus CVR. Acquisition targets NX-13, promising oral treatment for ulcerative colitis & Crohn's disease. Via Benzinga BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Agiliti, Inc. (NYSE – AGTI), Landos Biopharma, Inc. (Nasdaq – LABP), Fusion Pharmaceuticals Inc. (Nasdaq - FUSN), Kinnate Biopharma Inc. (Nasdaq – KNTE) March 25, 2024 From Brodsky & Smith LLC Via GlobeNewswire US Stocks Down; Chicago Fed National Activity Index Rises In February March 25, 2024 U.S. stocks traded lower this morning, with the Dow Jones index falling more than 50 points on Monday. Following the market opening Monday, the Dow traded down 0.16% to 39,412.36 while the NASDAQ fell... Via Benzinga Topics Economy Stocks Exposures Interest Rates US Equities 12 Health Care Stocks Moving In Monday's Pre-Market Session March 25, 2024 Via Benzinga LABP Stock Earnings: Landos Biopharma Misses EPS for Q4 2023 March 21, 2024 LABP stock results show that Landos Biopharma missed analyst estimates for earnings per share the fourth quarter of 2023. Via InvestorPlace Landos Biopharma - Investor Like It Better Than Analysts March 07, 2024 Landos Biopharma is a clinical stage biopharmaceutical company focused on the development of first-in-class therapeutics for patients with autoimmune disease. Via Talk Markets 12 Health Care Stocks Moving In Tuesday's Pre-Market Session June 13, 2023 Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session June 08, 2023 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session April 12, 2023 Via Benzinga Roku Has 26% Of Cash With SVB Financial, Deposit Recovery Uncertain — 27 Other Companies With Ties To Collapsed Bank March 11, 2023 The collapse of SVB Financial Group (NASDAQ: SIVB) could have a ripple effect on the technology and biotech industries, the two largest sectors that had deposits and financial relationships with the... Via Benzinga 12 Health Care Stocks Moving In Thursday's Pre-Market Session March 09, 2023 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday March 09, 2023 It's time for another breakdown of the biggest pre-market stock movers traders will want to know about on Thursday morning! Via InvestorPlace 12 Health Care Stocks Moving In Wednesday's After-Market Session March 08, 2023 Via Benzinga Why Reata Pharmaceuticals Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket March 01, 2023 Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. Via Benzinga Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder February 28, 2023 From Landos Biopharma, Inc. Via GlobeNewswire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.